Antitumor activity against human LU99 cells xenografted in BALB/cSLC-nu/nu mouse assessed as tumor growth inhibition at 5 mg/kg, iv qd administered for 14 days measured on day 15 relative to control
Antitumor activity against human LU99 cells xenografted in BALB/cSLC-nu/nu mouse assessed as tumor growth inhibition at 40 mg/kg, iv administered in liposomal formulation on day 1, 4, 8, 11, 15, 18 measured on day 22 relative to control
Antitumor activity against human LU99 cells xenografted in BALB/cSLC-nu/nu mouse assessed as tumor growth inhibition at 100 mg/kg, po qd administered for 14 days measured on day 15 relative to control
Antiproliferative activity against human LU99 cells expressing KRAS G12C mutant assessed as cell growth inhibition cultured in soft agar medium containing compounds and supplemented with fresh medium for every 7 days by 3D soft agar proliferation assay
Antiproliferative activity against human LU99 cells expressing KRAS G12C mutant assessed as cell growth inhibition measured after 5 days by sytox green dye staining based 2D proliferation assay
Antitumor activity against MTAP/CDKN2A deleted human Lu-99 cells xenografted in Hsd athymic nude mouse assessed as tumor growth inhibition at 50 mg/kg, po qd administered via oral gavage for 21 days by caliper method relative to control
Antitumor activity against MTAP/CDKN2A deleted human Lu-99 cells xenografted in Hsd athymic nude mouse assessed as tumor growth inhibition at 100 mg/kg, po qd administered via oral gavage for 21 days by caliper method relative to control
Antitumor activity against MTAP/CDKN2A deleted human Lu-99 cells xenografted in Hsd athymic nude mouse assessed as reduction in PRMT5 mediated SDMA level in tumor at 12.5 to 100 mg/kg, po qd administered via oral gavage for 21 days relative to control